CuraScript

CuraScript is a healthcare distribution company specializing in specialty pharmaceuticals and medical supplies. It focuses on delivering essential injectables and infused medications to healthcare providers, enhancing operational efficiency and patient care. CuraScript, founded in 1989 in Orlando, US, specializes in the distribution of specialty pharmaceuticals, including injectables and infused medications. In 2004, the company was acquired by Express Scripts for approximately USD 335 mn.

The company has engaged in 2 deals in total, with its most recent deal occurring on February 1, 2004. CuraScript SD specializes in the distribution of specialty pharmaceuticals and healthcare products, focusing on injectables, infused medications, and necessary medical supplies. Their offerings are tailored to meet the needs of medical providers, aiming to streamline operations by reducing waste and ensuring timely access to essential products. The company serves a diverse range of clients within the healthcare sector, including hospitals, specialty pharmacies, and clinics across various specialties such as oncology, neurology, and pediatrics.

Their products are widely distributed in the United States, particularly in markets requiring specialized medical treatments, such as gene and cell therapy, as well as those addressing rare diseases. By facilitating access to these vital healthcare resources, CuraScript SD plays a crucial role in enhancing patient care and operational efficiency for its clientele. CuraScript SD generates revenue through B2B transactions with healthcare providers and institutions. The company operates using a structured approach to pricing and distribution, allowing medical providers to procure specialty pharmaceuticals and related services efficiently.

Their revenue model includes partnerships with healthcare entities and the provision of specialized distribution services, which may involve negotiated contracts for bulk purchasing. Clients benefit from a tailored product catalog, which includes flagship offerings designed to meet the unique needs of various specialties. Revenue flows from these business relationships, reflecting a commitment to quality service and the provision of necessary medical products that enhance patient outcomes. CuraScript plans to leverage the strategic support from its acquisition by Express Scripts to enhance its market presence.

This includes a focus on introducing new products related to specialty pharmaceuticals, with specific launch dates yet to be announced. The company aims to expand into additional markets within the U. S. , particularly focusing on regions that require advanced therapeutic treatments by the end of 2024.

The recent funding of USD 335 mn from the acquisition will be utilized to support these initiatives and facilitate growth in targeted areas.